Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. / Haddow, Lewis J; Laverick, Rosanna; Daskalopoulou, Marina; McDonnell, Jeffrey; Lampe, Fiona C; Gilson, Richard; Speakman, Andrew; Antinori, Andrea; Balestra, Pietro; Bruun, Tina; Gerstoft, Jan; Nielsen, Lars; Vassilenko, Anna; Collins, Simon; Rodger, Alison J; Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group.

In: AIDS & Behavior, Vol. 22, No. 5, 05.2018, p. 1573–1583.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Haddow, LJ, Laverick, R, Daskalopoulou, M, McDonnell, J, Lampe, FC, Gilson, R, Speakman, A, Antinori, A, Balestra, P, Bruun, T, Gerstoft, J, Nielsen, L, Vassilenko, A, Collins, S, Rodger, AJ & Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group 2018, 'Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients', AIDS & Behavior, vol. 22, no. 5, pp. 1573–1583. https://doi.org/10.1007/s10461-017-1683-z

APA

Haddow, L. J., Laverick, R., Daskalopoulou, M., McDonnell, J., Lampe, F. C., Gilson, R., Speakman, A., Antinori, A., Balestra, P., Bruun, T., Gerstoft, J., Nielsen, L., Vassilenko, A., Collins, S., Rodger, A. J., & Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group (2018). Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. AIDS & Behavior, 22(5), 1573–1583. https://doi.org/10.1007/s10461-017-1683-z

Vancouver

Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R et al. Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. AIDS & Behavior. 2018 May;22(5):1573–1583. https://doi.org/10.1007/s10461-017-1683-z

Author

Haddow, Lewis J ; Laverick, Rosanna ; Daskalopoulou, Marina ; McDonnell, Jeffrey ; Lampe, Fiona C ; Gilson, Richard ; Speakman, Andrew ; Antinori, Andrea ; Balestra, Pietro ; Bruun, Tina ; Gerstoft, Jan ; Nielsen, Lars ; Vassilenko, Anna ; Collins, Simon ; Rodger, Alison J ; Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group. / Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. In: AIDS & Behavior. 2018 ; Vol. 22, No. 5. pp. 1573–1583.

Bibtex

@article{a0615307494e49aa878219061e3f51fa,
title = "Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients",
abstract = "We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤-1 in at least 2 out of 5 cognitive domains. Participants' mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm3; 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54-0.94) or with a university education (aPR 0.72, 95% CI 0.54-0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09-2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03-1.90).",
author = "Haddow, {Lewis J} and Rosanna Laverick and Marina Daskalopoulou and Jeffrey McDonnell and Lampe, {Fiona C} and Richard Gilson and Andrew Speakman and Andrea Antinori and Pietro Balestra and Tina Bruun and Jan Gerstoft and Lars Nielsen and Anna Vassilenko and Simon Collins and Rodger, {Alison J} and {Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group}",
year = "2018",
month = may,
doi = "10.1007/s10461-017-1683-z",
language = "English",
volume = "22",
pages = "1573–1583",
journal = "AIDS & Behavior",
issn = "1090-7165",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients

AU - Haddow, Lewis J

AU - Laverick, Rosanna

AU - Daskalopoulou, Marina

AU - McDonnell, Jeffrey

AU - Lampe, Fiona C

AU - Gilson, Richard

AU - Speakman, Andrew

AU - Antinori, Andrea

AU - Balestra, Pietro

AU - Bruun, Tina

AU - Gerstoft, Jan

AU - Nielsen, Lars

AU - Vassilenko, Anna

AU - Collins, Simon

AU - Rodger, Alison J

AU - Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group

PY - 2018/5

Y1 - 2018/5

N2 - We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤-1 in at least 2 out of 5 cognitive domains. Participants' mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm3; 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54-0.94) or with a university education (aPR 0.72, 95% CI 0.54-0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09-2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03-1.90).

AB - We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤-1 in at least 2 out of 5 cognitive domains. Participants' mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm3; 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54-0.94) or with a university education (aPR 0.72, 95% CI 0.54-0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09-2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03-1.90).

U2 - 10.1007/s10461-017-1683-z

DO - 10.1007/s10461-017-1683-z

M3 - Journal article

C2 - 28144792

VL - 22

SP - 1573

EP - 1583

JO - AIDS & Behavior

JF - AIDS & Behavior

SN - 1090-7165

IS - 5

ER -

ID: 195045466